Singapore, 5 Feb 2018 – Medical technology firm QT Vascular is potentially selling its coronary products to a multinational firm. QT Vascular is a global company listed in the Singapore Stock Exchange (SGX) that develops new and differentiated therapeutic solutions to address specific unmet clinical needs in the treatment of complex vascular disease.
QT Vascular Ltd. is the parent holding company of TriReme Medical (Singapore) Pte Ltd. It was formed in 2010 to provide support services to our Group and to develop, sell, assemble and commercialize medical devices.
On Monday morning, the term sheet both have entered into is non-legally binding and non-definitive, and it will continue to engage the buyer with the intention to complete the deal.
The Catalist-listed firm aims to continue generating value for shareholders from its mature products while further developing its drug-coated products and expanding its portfolio with new technologies.
QT Vascular had also announced a potential transaction linked to certain coronary assets in October last year, which led to a surge in its share price.
